Old Web
English
Sign In
Acemap
>
authorDetail
>
Peter Lawrence
Peter Lawrence
AstraZeneca
Medicine
Cancer
Pharmacodynamics
Pharmacokinetics
Tolerability
10
Papers
189
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
2018
Cancer Chemotherapy and Pharmacology
Emma Dean
Udai Banerji
Jan H. M. Schellens
Matthew G Krebs
Begona Jimenez
Emilie M.J. van Brummelen
Christopher Bailey
Ed Casson
Diana Cripps
Marie Cullberg
Stephen Evans
Andrew Foxley
Justin P.O. Lindemann
Paul Rugman
Nigel Phillip Taylor
Guy Turner
James Yates
Peter Lawrence
Show All
Source
Cite
Save
Citations (8)
Complexity of FGFR signalling in metastatic urothelial cancer.
2015
Journal of Hematology & Oncology
Alejo Rodriguez-Vida
Matilde Saggese
Simon Hughes
Sarah Rudman
S. Chowdhury
Neil R. Smith
Peter Lawrence
Claire Rooney
Brian Dougherty
Donal Landers
Elaine Kilgour
Hendrik-Tobias Arkenau
Show All
Source
Cite
Save
Citations (22)
Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.
2014
Journal of Clinical Oncology
Paul Elvin
Amy Palmer
Chris Womack
M. Tall
Karen E Swales
Michelle D. Garrett
Udai Banerji
Kenji Tamura
S. Y. Amy Cheung
Peter Lawrence
Justin Lindemann
Helen Ambrose
Christine Stephens
Barry R. Davies
Andrew Foxley
Martin Pass
Elizabeth A. Harrington
J. Carl Barrett
Show All
Source
Cite
Save
Citations (5)
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors
2013
Fabrice Andre
Malcolm R Ranson
Emma Dean
Andrea Varga
Ruud van der Noll
Paul Stockman
Dana Ghiorghiu
Elaine Kilgour
Paul D. Smith
Merran Macpherson
Peter Lawrence
Andrew Hastie
Jan H. M. Schellens
Show All
Source
Cite
Save
Citations (26)
Results of two Phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.
2013
Udai Banerji
Malcolm R Ranson
Jan H. M. Schellens
Taito Esaki
Emma Dean
Andrea Zivi
Ruud van der Noll
Paul Stockman
Marcelo Marotti
Michelle D. Garrett
Barry R. Davies
Paul Elvin
Andrew Hastie
Peter Lawrence
Sy Amy Cheung
Christine Stephens
Kenji Tamura
Show All
Source
Cite
Save
Citations (2)
1